Novo Nordisk’s Q1 2024 Revenue Surges: Up by 22% in Danish Kroner, 24% at Constant Exchange Rates, Reaching DKK 65.3 Billion
Novo Nordisk’s Q1 2024 Performance Highlights Growth and Expansion Novo Nordisk, a global healthcare company focusing on diabetes and other serious chronic diseases, has reported robust financial results for the…
I Lost the Ability to Speak, Walk, or Sit: A Glimpse into a Rare Autoimmune Disease Targeting Muscles
In January 2016, Elisa Glass began feeling fatigued and unsteady. As her symptoms worsened to include severe body aches and weakness reminiscent of painful charley horses, she sought help from…
WuXi AppTec Surpasses First Quarter 2024 Goals Amid External Obstacles, Sustaining Operational Stability
WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industry, has released its financial results for the first quarter ending March 31,…
Merck Presents Cutting-Edge Pharma and Electronic Materials Production to Robert Habeck
CVS Health Corporation (NYSE: CVS) unveiled its financial performance for the first quarter ending March 31, 2024, showcasing robust revenue growth alongside strategic adjustments to its annual guidance. First Quarter…
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Amgen (NASDAQ: AMGN) has announced the unveiling of groundbreaking respiratory research at the American Thoracic Society (ATS) 2024 International Conference, scheduled from May 12 to May 22 in San Diego.…
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a…
FDA Fully Approves TIVDAK® for Treating Recurrent or Metastatic Cervical Cancer
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) have received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab…
AstraZeneca Highlights ATS 2024 Research in Respiratory and Immune Diseases, Emphasizing Pipeline Strength
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA…
CHMP Recommends Approval of Truqap and Faslodex in the EU for Advanced ER-Positive Breast Cancer Patients
AstraZeneca’s Truqap (capivasertib) combined with Faslodex (fulvestrant) has received a positive recommendation for approval in the European Union (EU) for treating adult patients with locally advanced or metastatic breast cancer…
Enhertu Shows Promising Results in Advanced Breast Cancer Study
The DESTINY-Breast06 Phase III trial yielded encouraging results, demonstrating the effectiveness of Enhertu (trastuzumab deruxtecan) in improving progression-free survival (PFS) significantly and meaningfully compared to standard chemotherapy. This positive outcome…
AbbVie Bolsters Dedication to Science and Innovation: Allocates €150 Million for State-of-the-Art Research Hub in Germany
AbbVie Initiates Construction of State-of-the-Art Research Hub, “LUnA,” in Germany with €150 Million Investment AbbVie has commenced the construction of its new central research building, dubbed “LUnA” (LUdwighafens neue Arbeitswelt),…
Merck Unveils Promising Results for V116, Advanced Pneumococcal Vaccine for Adults
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has revealed findings from its Phase 3 trial, STRIDE-10, assessing V116, the company’s advanced 21-valent pneumococcal…